Outcomes of Rituximab and Bendamustine Induction Regimen VS Cytarabine-Based Induction for Patients with Mantle Cell Lymphoma

被引：0
|
作者：
Alnimer, Yanal [1 ]
Yalniz, Fevzi [2 ]
Monohan, Gregory [2 ]
Munker, Reinhold [2 ]
Qasrawi, Ayman [3 ]
Iragavarapu, Chait [3 ]
Amr, Mahmoud [3 ]
机构：
[1] Univ Kentucky, Tappahannock, VA USA
[2] Univ Kentucky, Dept Hematol, Lexington, KY USA
[3] Univ Kentucky, Lexington, KY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-211992
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6320 / 6321
页数：2
相关论文
共 50 条
  • [31] Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy
    Ratnasingam, Sumita
    Gilbertson, Michael
    McQuilten, Zoe
    Htun, Kay T.
    Grigoriadis, George
    Htet, Swe Myo
    Campbell, Philip
    Chai, Khai Li
    Quach, Hang
    Patil, Sushrut S.
    Shortt, Jake
    Opat, Stephen
    BLOOD, 2016, 128 (22)
  • [32] A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP plus /- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma
    Wang, Hui
    Xing, Lijie
    Liu, Dan
    Wei, Haichen
    Lu, Ke
    He, Qiang
    Xie, Linna
    Ma, Ji
    Qiu, Lugui
    Li, Zengjun
    BLOOD, 2024, 144 : 6307 - 6308
  • [33] The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines
    Visco, Carlo
    Castegnaro, Silvia
    Chieregato, Katia
    Bernardi, Martina
    Albiero, Elena
    Zanon, Cristina
    Madeo, Domenico
    Rodeghiero, Francesco
    BLOOD CELLS MOLECULES AND DISEASES, 2012, 48 (01) : 68 - 75
  • [34] Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
    Visco, Carlo
    Finotto, Silvia
    Zambello, Renato
    Paolini, Rossella
    Menin, Andrea
    Zanotti, Roberta
    Zaja, Francesco
    Semenzato, Gianpietro
    Pizzolo, Giovanni
    D'Amore, Emanuele S. G.
    Rodeghiero, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) : 1442 - 1449
  • [35] Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab
    Kourelis, Taxiarchis V.
    Kahl, Brad S.
    Benn, Peter
    Delach, Judith A.
    Bilgrami, Syed F.
    ACTA HAEMATOLOGICA, 2011, 126 (01) : 40 - 43
  • [36] Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
    Visco, Carlo
    Tisi, Maria C.
    Evangelista, Andrea
    Di Rocco, Alice
    Zoellner, Anna-Katharina
    Zilioli, Vittorio R.
    Hohaus, Stefan
    Sciarra, Roberta
    Re, Alessandro
    Tecchio, Cristina
    Chiappella, Annalisa
    Morello, Lucia
    Gini, Guido
    Nassi, Luca
    Perrone, Tommasina
    Molinari, Anna L.
    Fabbri, Alberto
    Cox, Maria C.
    Finolezzi, Erica
    Ferrero, Simone
    Puccini, Benedetta
    De Celis, Isabel Alvarez
    Arcari, Annalisa
    Marino, Dario
    Merli, Michele
    Piazza, Francesco
    Gentile, Massimo
    Pelosini, Matteo
    Loseto, Giacomo
    Hermine, Olivier
    Dreyling, Martin
    Ruggeri, Marco
    Martelli, Maurizio
    Hoster, Eva
    Vitolo, Umberto
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 940 - 944
  • [37] Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
    Wang, Michael L.
    Jurczak, Wojciech
    Jerkeman, Mats
    Trotman, Judith
    Zinzani, Pier L.
    Belada, David
    Boccomini, Carola
    Flinn, Ian W.
    Giri, Pratyush
    Goy, Andre
    Hamlin, Paul A.
    Hermine, Olivier
    Hernandez-Rivas, Jose-Angel
    Hong, Xiaonan
    Kim, Seok Jin
    Lewis, David
    Mishima, Yuko
    Ozcan, Muhit
    Perini, Guilherme F.
    Pocock, Christopher
    Song, Yuqin
    Spurgeon, Stephen E.
    Storring, John M.
    Walewski, Jan
    Zhu, Jun
    Qin, Rui
    Henninger, Todd
    Deshpande, Sanjay
    Howes, Angela
    Le Gouill, Steven
    Dreyling, Martin
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (26) : 2482 - 2494
  • [38] RITUXIMAB BENDAMUSTINE CYTARABINE IS A FEASIBLE AND SAFE INDUCTION REGIMEN PRIOR TO ASCT IN FRONTLINE MCL: A SINGLE CENTER RETROSPECTIVE REAL LIFE EVALUATION
    Gianesello, I.
    Nabergoj, M.
    Branca, A.
    Berno, T.
    Lessi, F.
    Riva, M.
    De March, E.
    Zambello, R.
    Trentin, L.
    Piazza, F.
    Semenzato, G.
    HAEMATOLOGICA, 2017, 102 : 695 - 695
  • [39] RITUXIMAB AND HIGH DOSE CYTARABINE WITH AUTOLOGOUS TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
    Burrows, S.
    Tucker, D.
    Naylor, G.
    Wardrope, K.
    Bolam, S.
    McKay, P.
    Forbes, A.
    Rule, S.
    HAEMATOLOGICA, 2016, 101 : 398 - 399
  • [40] Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience
    Branca, Antonio
    Gianesello, Ilaria
    Brugnaro, Luca
    Berno, Tamara
    Imbergamo, Silvia
    Lessi, Federica
    Sammartin, Kety
    Vianello, Fabrizio
    Adami, Fausto
    Binotto, Gianni
    Gurrieri, Carmela
    Trentin, Livio
    Visco, Carlo
    Zambello, Renato
    Piazza, Francesco
    Semenzato, Gianpietro
    BLOOD, 2015, 126 (23)
12345